ARCHIVES

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

This article is from The Cancer Letter archive.

Vol. 39 No. 18 | May 8, 2013

Download PDF Visit The Full Archive

Related Articles

Bristol-Myers Adds Georgetown, MSK to Program

May 1, 1981

Chemoprevention Clinical Trials To starts In 1982 If Greenwald, DRCCA Board Can Move Fast Enough

August 28, 1981

In Brief: NTP Invites Comments On Annual Carcinogen Report At April 21 Meeting; Robert Mosely Dies

March 27, 1987

In Brief: Richard Fisher Named Fox Chase President and CEO

August 2, 2013

In Brief: Mark Kochevar Named New Administrative Officer Of DCE; Thomas Necheles Dies Suddenly at 51

September 21, 1984

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014